KPRX

2.63

1.50% -0.04

Handel nachbörslich: 2.60 -0.03 -1.14%

Kiora Pharmaceuticals Inc (KPRX)

Überblick Nachrichten Preisverlauf Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.67

Offen:

$2.623

24-Stunden-Volumen:

2,357

Relative Volume:

0.13

Marktkapitalisierung:

$11.64M

Einnahmen:

$20,000

Nettoeinkommen (Verlust:

$-11.06M

KGV:

-0.9245

EPS:

-2.8449

Netto-Cashflow:

$-10.53M

1W Leistung:

-4.71%

1M Leistung:

+1.54%

6M Leistung:

+28.92%

1J Leistung:

+2.26%

1-Tages-Spanne:

$2.60

$2.63

1-Wochen-Bereich:

$2.58

$2.80

52-Wochen-Spanne:

$1.7645

$2.95

Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile

Firmenname

Kiora Pharmaceuticals Inc

Sektor

Healthcare (1067)

Branche

Biotechnology (595)

Telefon

858-224-9600

Adresse

169 SAXONY RD., ENCINITAS

Mitarbeiter

Twitter

Nächster Verdiensttermin

2026-11-06

Neueste SEC-Einreichungen

KPRX's Discussions on Twitter

Compare KPRX vs VRTX, REGN, MRNA, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
KPRX Kiora Pharmaceuticals Inc	2.63	11.64M	20,000	-11.06M	-10.53M	-2.8449
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Kiora Pharmaceuticals Inc Aktie (KPRX) Neueste Nachrichten

Sep 18, 2026

Kiora Pharmaceuticals Inc (NYSE: KPRX) Stock Price, News & Analysis - kalkine.ca

Sep 18, 2026

Sep 17, 2026

New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX) - Stock Titan

Sep 17, 2026

Sep 08, 2026

Kiora Pharmaceuticals names Keith Lane clinical development head By Investing.com - Investing.com Canada

Sep 08, 2026

Kiora Pharmaceuticals names Keith Lane clinical development head - Investing.com

Sep 08, 2026

Kiora hires an executive who oversaw more than 60 eye-drug trials - Stock Titan

Sep 08, 2026

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs - TMX Newsfile

Sep 08, 2026

Sep 04, 2026

Kiora Pharmaceuticals Inc (NASDAQ: KPRX) Stock Price, News & Analysis - Kalkine

Sep 04, 2026

Aug 29, 2026

KPRX Q2 2026 Earnings: Narrower Loss Beats Estimates, Stock Still Slips 1.5%ROE Trend Analysis - careplusvn.com

Aug 29, 2026

Aug 21, 2026

Form 8K Kiora Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria

Aug 19, 2026

Kiora Licenses KIO-301 Rights in South Korea - TipRanks

Aug 19, 2026

Kiora Pharmaceuticals Licenses KIO-301 South Korea Rights to Chong Kun Dang for $1 Million Upfront Plus Milestones and Royalties - kalkine.ca

Aug 19, 2026

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation - Yahoo Finance

Aug 19, 2026

Aug 14, 2026

Perceptive Advisors LLC Acquires New Position in Kiora Pharmaceuticals Inc (KPRX) - GuruFocus

Aug 14, 2026

ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants - Stock Titan

Aug 14, 2026

Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing - Stock Titan

Aug 14, 2026

Aug 11, 2026

Kiora Pharmaceuticals (KPRX) Rises 1.55% as Biotech Stock Holds Key Support at $2.49ATR Stop - dars.gov.et

Aug 11, 2026

Aug 10, 2026

Kiora Pharmaceuticals (KPRX) reports 9.99% stake held by Perceptive group - Stock Titan

Aug 10, 2026

Aug 08, 2026

Form 8K Kiora Pharmaceuticals Inc For: 7 August By Investing.com - Investing.com Nigeria

Aug 08, 2026

Kiora Pharmaceuticals advances retinal disease trials, secures $24M funding, expects data in 2027 - Pluang

Aug 08, 2026

Aug 07, 2026

Kiora Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2026

Kiora Pharmaceuticals Reports Q2 2026 Results, Advances KIO-301 and KIO-104 Trials With Runway Into Late 2028 - kalkine.ca

Aug 07, 2026

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - TMX Newsfile

Aug 07, 2026

Aug 05, 2026

Kiora Pharmaceuticals (KPRX) Gains 2.83% as Shares Approach $2.67 ResistanceGap and Reverse - dars.gov.et

Aug 05, 2026

Aug 04, 2026

Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a shareEarnings Preview - TradingView

Aug 04, 2026

Jul 27, 2026